View Financial HealthOptimind Pharma 配当と自社株買い配当金 基準チェック /06Optimind Pharma配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).お知らせ • Jul 05Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in fundingOptimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).Board Change • Jan 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 11Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023).お知らせ • Jan 10Optimind Pharma Corp. Announces Executive ChangesOptimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors.Reported Earnings • Nov 01Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023).Reported Earnings • Jul 30First quarter 2024 earnings releasedFirst quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023).お知らせ • May 19Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023.お知らせ • Sep 21Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022.決済の安定と成長配当データの取得安定した配当: OMNDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: OMNDの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Optimind Pharma 配当利回り対市場OMND 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (OMND)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.4%業界平均 (Healthcare)2.0%アナリスト予想 (OMND) (最長3年)n/a注目すべき配当: OMNDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: OMNDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: OMNDの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: OMNDが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/09 06:53終値2025/09/11 00:00収益2025/08/31年間収益2025/02/28データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Optimind Pharma Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.
Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).
New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).
Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).
Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).
Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).
Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).
お知らせ • Jul 05Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in fundingOptimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.
Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).
Board Change • Jan 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 11Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023).
お知らせ • Jan 10Optimind Pharma Corp. Announces Executive ChangesOptimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors.
Reported Earnings • Nov 01Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023).
Reported Earnings • Jul 30First quarter 2024 earnings releasedFirst quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023).
お知らせ • May 19Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023.
お知らせ • Sep 21Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022.